Cell-mediated immune responses to respiratory syncytial virus infection: Magnitude, kinetics, and correlates with morbidity and age

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 1047-1056

  Geevarghese, Bessey ^a   Weinberg, Adriana ^a,b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cell mediated immunity; Morbidity; Respiratory syncytial virus; Th1; Th17; Th2; Th22; Th9

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CELL KINETICS; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HELPER CELL; HOSPITALIZATION; HUMAN; INFANT; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; MORBIDITY; PATHOGEN CLEARANCE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TH9 CELL; AGE; CELL PROLIFERATION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LENGTH OF STAY; PATHOLOGY; PRESCHOOL CHILD; SECRETION (PROCESS); T LYMPHOCYTE; TIME FACTOR;

AGE FACTORS; CELL PROLIFERATION; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; INFANT; INTERFERON-GAMMA; LENGTH OF STAY; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899812859     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27908     Document Type: Article

References (50)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917-28; PMID:11419430; http://dx.doi.org/10.1056/ NEJM200106213442507
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-55; PMID:20399493; http://dx.doi.org/10.1016/S0140-6736(10)60206-1
3. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis 2012; 206:56-62; PMID:22529314; http://dx.doi.org/10.1093/infdis/jis309
4. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104; PMID:15747245; http://dx.doi.org/10.1086/427813
5. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr., Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42; PMID:11010838; http://dx.doi.org/10.1086/315859
6. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999; 73:8485-95; PMID:10482601
7. Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 2004; 78:6024-32; PMID:15141000; http://dx.doi.org/10.1128/JVI.78.11.6024-6032.2004
8. Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol 2012; 24:303-7; PMID:22365614; http://dx.doi.org/10.1016/j.coi.2012.02.001
9. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012; 1247:56-68; PMID:22235761; http://dx.doi.org/10.1111/j.1749- 6632.2011.06351.x
10. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-6; PMID:17433650; http://dx.doi.org/10.1016/j. coi.2007.04.005
11. Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, Bernstein JA, Huston DP, Liu YJ. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 2010; 207:2479-91; PMID:20921287; http://dx.doi.org/10.1084/jem.20101376
12. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119:3573-85; PMID:19920355
13. Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem 2011; 353:41-6; PMID:21384158; http://dx.doi.org/10.1007/s11010-011-0772-y
14. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012; 484:514-8; PMID:22466287; http://dx.doi.org/10.1038/nature10957
15. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-7; PMID:18563156; http://dx.doi.org/10. 1038/nature07036
16. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82:2040-55; PMID:17928346; http://dx.doi.org/10.1128/JVI.01625-07
17. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007; 17:5-34; PMID:17004293; http://dx.doi.org/10. 1002/rmv.518
18. Oshansky CM, Zhang W, Moore E, Tripp RA. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol 2009; 4:279-97; PMID:19327115; http://dx.doi.org/10.2217/fmb.09.1
19. Stevens WW, Sun J, Castillo JP, Braciale TJ. Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. Viral Immunol 2009; 22:243-51; PMID:19594395; http://dx.doi.org/10.1089/vim.2009.0016
20. Dodd JS, Lum E, Goulding J, Muir R, Van Snick J, Openshaw PJ. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol 2009; 183:7006-13; PMID:19915054; http://dx.doi.org/10.4049/jimmunol.0900085
21. McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Lancet 2004; 363:1031-7; PMID:15051283; http://dx.doi.org/10.1016/S0140-6736(04)15838-8
22. Xing J, Wu Y, Ni B. Th9: a new player in asthma pathogenesis? J Asthma 2011; 48:115-25; PMID:21294663; http://dx.doi.org/10.3109/02770903.2011.554944
23. Blanco JC, Boukhvalova MS, Shirey KA, Prince GA, Vogel SN. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 2010; 6:482-92; PMID:20671419; http://dx.doi.org/10.4161/hv.6.6.11562
24. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol 2000; 105:108-15; PMID:10629460; http://dx.doi.org/10.1016/S0091-6749(00)90185-4
25. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, Holroyd KJ, Nicolaides NC. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol 1999; 103:S485-91; PMID:10329852; http://dx.doi.org/10.1016/S0091-6749(99)70165-X
26. Mesquita D Jr., Cruvinel WM, Câmara NO, Kállas EG, Andrade LE. Autoimmune diseases in the TH17 era. Braz J Med Biol Res 2009; 42:476-86; PMID:19448894; http://dx.doi.org/10.1590/S0100-879X2009000600002
27. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med 2009; 206:313-28; PMID:19204109; http://dx.doi.org/10.1084/jem.20082030
28. Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, Hayashi H, Iwakura Y, Yoshimoto T, Akatsuka T, Matsui M. IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J Immunol 2007; 179:3917-25; PMID:17785829
29. Román M, Calhoun WJ, Hinton KL, Avendaño LF, Simon V, Escobar AM, Gaggero A, Díaz PV. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med 1997; 156:190-5; PMID:9230746; http://dx.doi.org/10.1164/ajrccm.156.1. 9611050
30. Bueno SM, González PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, Fennelly GJ, Eugenin EA, Jacobs WR Jr., Riedel CA, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A 2008; 105:20822-7; PMID:19075247; http://dx.doi.org/10.1073/pnas.0806244105
31. Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol 2008; 181:7958-68; PMID:19017987
32. Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008; 82:2196-207; PMID:18094193; http://dx.doi.org/10.1128/JVI.01949-07
33. Lee YM, Miyahara N, Takeda K, Prpich J, Oh A, Balhorn A, Joetham A, Gelfand EW, Dakhama A. IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 2008; 177:208-18; PMID:17962634; http://dx.doi.org/10.1164/rccm.200612- 1890OC
34. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy - a review. Virus Genes 2006; 33:235-52; PMID:16972040
35. Anderson LJ, Tsou C, Potter C, Keyserling HL, Smith TF, Ananaba G, Bangham CR. Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. J Infect Dis 1994; 170:1201-8; PMID:7963714; http://dx.doi.org/10.1093/infdis/170.5.1201
36. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 2001; 184:355-8; PMID:11443563; http://dx.doi.org/10.1086/322035
37. Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V, Drazenovic V, Mlinaric-Galinovic G, Rabatic S. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin Exp Immunol 2000; 121:332-8; PMID:10931150; http://dx.doi.org/10.1046/j.1365-2249.2000.01297.x
38. Chen ZM, Mao JH, Du LZ, Tang YM. Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection. Acta Paediatr 2002; 91:914-22; PMID:12412865; http://dx.doi.org/10.1111/j.1651-2227. 2002.tb02877.x
39. th, Jones L, Moscatiello C, Keyserling H, Anderson LJ. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J Infect Dis 2002; 185:1388-94; PMID:11992272; http://dx.doi.org/10.1086/340505
40. Guo H, Topham DJ. Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. J Virol 2010; 84:7750-9; PMID:20504940; http://dx.doi.org/10.1128/ JVI.00187-10
41. Taube C, Tertilt C, Gyülveszi G, Dehzad N, Kreymborg K, Schneeweiss K, Michel E, Reuter S, Renauld JC, Arnold-Schild D, et al. IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS One 2011; 6:e21799; PMID:21789181; http://dx.doi.org/10.1371/journal.pone. 0021799
42. Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, Schaller M, Behrendt H, Ring J, Schmidt-Weber CB, et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol 2011; 41:1894-901; PMID:21469124; http://dx.doi.org/10.1002/eji.201041197
43. Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol 2008; 180:2376-84; PMID:18250447
44. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003; 168:633-9; PMID:12773328; http://dx.doi.org/10.1164/ rccm.200210-1148OC
45. Lukacs NW, Tekkanat KK, Berlin A, Hogaboam CM, Miller A, Evanoff H, Lincoln P, Maassab H. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. J Immunol 2001; 167:1060-5; PMID:11441116
46. Nicolaides NC, Holroyd KJ, Ewart SL, Eleff SM, Kiser MB, Dragwa CR, Sullivan CD, Grasso L, Zhang LY, Messler CJ, et al. Interleukin 9: a candidate gene for asthma. Proc Natl Acad Sci U S A 1997; 94:13175-80; PMID:9371819; http://dx.doi.org/10.1073/pnas.94.24.13175
47. Soussi-Gounni A, Kontolemos M, Hamid Q. Role of IL-9 in the pathophysiology of allergic diseases. J Allergy Clin Immunol 2001; 107:575-82; PMID:11295641; http://dx.doi.org/10.1067/mai.2001.114238
48. Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, Stewart JP, Smyth RL, Hart CA. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One 2007; 2:e1038; PMID:17940602; http://dx.doi.org/10.1371/journal.pone.0001038
49. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002; 196:1381-6; PMID:12438429; http://dx.doi.org/10.1084/ jem.20020943
50. Weinberg A, Song LY, Wilkening C, Sevin A, Blais B, Louzao R, Stein D, Defechereux P, Durand D, Riedel E, et al.; Pediatric ACTG Cryopreservation Working Group. Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol 2009; 16:1176-86; PMID:19515870; http://dx.doi.org/10.1128/ CVI.00342-08